Global Renal Biomarkers Market Insights Forecasts to 2033

• The Global Renal Biomarkers Market Size was Valued at USD 1,491.2 Million in 2023
• The Market Size is Growing at a CAGR of 7.53% from 2023 to 2033
• The Worldwide Renal Biomarkers Market Size is Expected to Reach USD 3,081.6 Million by 2033
• Asia Pacific is Expected to Grow the fastest during the forecast period.

The Global Renal Biomarkers Market Size is Anticipated to Exceed USD 3,081.6 Million by 2033, Growing at a CAGR of 7.53% from 2023 to 2033.

Market Overview

Renal biomarkers are constituents found in the blood or urine that can offer information regarding the functioning of the kidneys. Renal biomarkers consist of proteins, lipids, cells, microRNAs, metabolites, genes, or proteomic patterns present in a urinalysis. Renal biomarkers support the regulation of the glomerular filtration rate (GFR) of kidneys to examine their appropriate functioning and evaluate pathogenic procedures or pharmacological responses to therapeutic interventions. Real biomarkers also help in forecasting disease evolution and computing drug dosage, renal biomarkers find wide applications in hospitals and diagnostic laboratories around the world. There are types of renal biomarkers, such as functional biomarkers, upregulated proteins, and other biomarkers. Furthermore, renal biomarkers, involving blood urea nitrogen, serum creatinine, urinary albumin/protein, and volume excretion are used in the diagnosis of chronic kidney disease (CKD) and monitoring of the disease. The expansion of the global market is propelled by some factors. The main factor is, that the increasing incidence of renal diseases globally is propelling the demand for precise and consistent diagnostic tools. Furthermore, advanced technology and the development of advanced biomarker detection methods have enhanced the sensitivity, specialty, and precision of renal biomarker tests.

Report Coverage

This research report categorizes the market for the global renal biomarkers market based on various segments and regions forecasts revenue growth and analyzes trends in each submarket. The report analyses the key growth drivers, opportunities, and challenges influencing the global renal biomarkers market. Recent market developments and competitive strategies such as expansion, product launch, and development, partnership, merger, and acquisition have been included to draw the competitive landscape in the market. The report strategically identifies and profiles the key market players and analyses their core competencies in each sub-segment of the global renal biomarkers market.

Driving Factors

The major factors driving the growth of renal biomarkers are the increasing incidence of various kidney-related diseases, like chronic kidney disease, kidney failure, acute kidney injury, diabetes, and hypertension, which are the main causes of renal diseases, linked with rapid technological advancements in the area of genetics. Furthermore, early detection and treatment of kidney diseases is serious to prevent the progression of the disease to end-stage renal disease (ESRD). Renal biomarkers can aid in detecting kidney disorders at an early stage as soon as therapy is most important. Additionally, advanced diagnostic technologies, like proteomics, genomics, and metabolomics have extended the variety of available renal biomarkers.  The addition of these technologies to traditional diagnostic procedures has further propelled the demand for renal biomarkers. Personalized medicine is a healthcare procedure that reflects distinct patient factors, like genetics, lifestyle, and environment. Renal biomarkers offer the probability to adapt kidney disease therapy by identifying people who are more expected to respond to certain therapies. These factors drive the growth of the renal biomarkers market.

Restraining Factors

The biomarker regulatory environment is complex and dynamic. It might take a lot of time and resources to get regulatory clearances and meet strict quality and safety standards. The research and commercialization of biomarkers can present regulatory complications that hinder market expansion and inventiveness. Furthermore, there is still a lack of awareness among healthcare providers and patients regarding their value in renal disease management. Limited education and awareness related to the accessibility and benefits of renal biomarkers may restrain their extensive acceptance and application in clinical practice. Moreover, the low sensitivity and specificity of biomarkers are predicted to hamper the growth of the renal biomarkers market.

Market Segmentation

The global renal biomarkers market share is classified into type, diagnostic technique, and end user.                                                                                         

• The functional biomarker segment is anticipated to hold the largest share of the global renal biomarkers market during the forecast period.    

On the basis of the type, the global renal biomarkers market is divided into functional biomarker, up-regulated protein, and others. Among these, the functional biomarker segment is anticipated to hold the largest share of the global renal biomarkers market during the forecast period. Functional biomarkers are specific indicators or constituents that directly imitate the functional status of the kidneys. These biomarkers, including serum creatinine, glomerular filtration rate (GFR), and cystatin C, are broadly used in clinical practice to evaluate kidney function and diagnose renal illnesses. The conventional clinical significance and consistency of functional biomarkers make them the foremost choice for estimating renal health.

• The enzyme-linked immunosorbent assay (ELISA) segment is anticipated to hold the highest share of the global renal biomarkers market during the forecast period.

On the basis of the diagnostic technique, the global renal biomarkers market is divided into enzyme-linked immunosorbent assay (ELISA), particle-enhanced turbidimetric immunoassay (PETIA), colorimetric assay, chemiluminescent enzyme immunoassay (CLIA), and liquid chromatography mass spectrometry (LC-MS). Among these, the enzyme-linked immunosorbent assay (ELISA) segment is anticipated to hold the highest share of the global renal biomarkers market during the forecast period. ELISA tests can be completed rapidly and are easy to carry out subsequently they are intended to handle several samples in parallel quickly. This test signifies a very common choice for evaluating numerous research and diagnostic targets.

• The diagnostic laboratory segment is anticipated to hold the highest share of the global renal biomarkers market during the forecast period.

On the basis of the end user, the global renal biomarkers market is divided into hospital, diagnostic laboratory, and others. Among these, the diagnostic laboratory segment is anticipated to hold the highest share of the global renal biomarkers market during the forecast period. The rising incidence of kidney diseases, inventiveness by the government, and strategies commenced by the key market players are the main factors driving the surge in diagnostic laboratory, thus rising tests performed in these diagnostic laboratories. Moreover, the market for renal biomarkers used in laboratories is predicted to rise due to the partnership between the manufacturers and laboratories to produce advanced products.

Regional Segment Analysis of the Global Renal Biomarkers Market

• North America (U.S., Canada, Mexico) 
• Europe (Germany, France, U.K., Italy, Spain, Rest of Europe)
• Asia-Pacific (China, Japan, India, Rest of APAC)
• South America (Brazil and the Rest of South America) 
• The Middle East and Africa (UAE, South Africa, Rest of MEA)

North America is anticipated to hold the largest share of the global renal biomarkers market over the predicted timeframe.

North America is anticipated to hold the largest share of the global renal biomarkers market over the predicted timeframe. The expansion of North America is driven by factors, like the rising incidence of CKD and the geriatric population foremost to the demand for renal biomarkers for diagnosis of kidney disease. The growing incidence of chronic kidney diseases among people in the U.S. is a key factor credited to the rising use of renal biomarkers for effective diagnosis and to propel the growth of the market in this region. In addition, the progressively susceptible elderly population that is inclined to chronic kidney diseases in the United States is also contributing to the growing demand for early-stage diagnosis and operative treatment, thus contributing to the market growth. Moreover, the growing focus of government agencies in the U.S. on emerging and improving diagnostic tests for kidney disorders ultimately raises the demand for renal biomarkers. These factors drive the growth of the renal biomarkers market over the predicted timeframe in the North America region.

Asia-Pacific is anticipated to grow at the fastest rate in the global renal biomarkers market over the predicted timeframe. The fast growth of this region can be accredited to numerous factors, such as a huge patient population, rising awareness regarding renal disease, enhanced healthcare facilities, and growing healthcare spending. Furthermore, the rising acquisition of advanced diagnostic technologies, the development of understanding government creativities, and the presence of the huge available market contribute to the region's enhanced growth in the renal biomarkers market. The Asia Pacific region is anticipated to have an enormous rise in the need for efficient biomarkers to support diagnosis and treatment choices as healthcare systems in nations like China, India, and Japan continue to develop and concentrate on enhancing renal care. These factors drive the expansion of the renal biomarkers market over the predicted timeframe in the Asia Pacific region.

Competitive Analysis:

The report offers the appropriate analysis of the key organizations/companies involved within the global renal biomarkers market along with a comparative evaluation primarily based on their product offering, business overviews, geographic presence, enterprise strategies, segment market share, and SWOT analysis. The report also provides an elaborative analysis focusing on the current news and developments of the companies, which includes product development, innovations, joint ventures, partnerships, mergers & acquisitions, strategic alliances, and others. This allows for the evaluation of the overall competition within the market.

List of Key Companies

• Roche Diagnostics
• Thermo Fisher Scientific Inc.
• BioMérieux SA
• Ortho Clinical Diagnostics 
• Bio-Rad Laboratories, Inc.
• Quest Diagnostics Incorporated
• ACON Laboratories, Inc.
• R&D Systems, Inc. (Bio-Techne Corporation)
• DiaSorin S.p.A
• Siemens Healthineers
• Beckman Coulter, Inc.
• Randox Laboratories Ltd. 
• Nova Biomedical Corporation
• Sysmex Corporation
• Others

Key Target Audience

• Market Players
• Investors
• End-users
• Government Authorities 
• Consulting And Research Firm
• Venture capitalists
• Value-Added Resellers (VARs)

Recent Developments

• In February 2023, the new provider access portal, myIntelX, was launched, as reported by a company named Renalytix plc. Physicians across the country can request KidneyIntelX tests online through this website.

• In January 2023, a new blood test that can identify kidney illness early was developed by a team of researchers at the University of California, San Francisco. Based on a panel of biomarkers, the test known as KidneyIntelX can determine which patients are at risk of developing kidney disease.

Market Segment

This study forecasts revenue at global, regional, and country levels from 2020 to 2033. Spherical Insights has segmented the global renal biomarkers market based on the below-mentioned segments: 

Global Renal Biomarkers Market, By Type

• Functional Biomarker
• Up-regulated Protein
• Others

Global Renal Biomarkers Market, By Diagnostic Technique

• Enzyme-linked Immunosorbent Assay (ELISA)
• Particle-enhanced Turbidimetric Immunoassay (PETIA)
• Colorimetric Assay
• Chemiluminescent Enzyme Immunoassay (CLIA)
• Liquid Chromatography Mass Spectrometry (LC-MS)

Global Renal Biomarkers Market, By End User

• Hospital
• Diagnostic Laboratory
• Others

Global Renal Biomarkers Market, By Regional

• North America
  • US
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Russia
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Rest of Asia Pacific
• South America
  • Brazil
  • Argentina
  • Rest of South America
• Middle East & Africa
  • UAE
  • Saudi Arabia
  • Qatar
  • South Africa
  • Rest of the Middle East & Africa